Major Depressive Disorder Clinical Trials in Saint Charles, Missouri
5 studies are recruiting for major depressive disorder in Saint Charles, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
- Stage
- Phase 3
- Ages
- 18 to 74
- Site
- St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles, Missouri
- Locations
- 50 in total
- Run by
- Xenon Pharmaceuticals Inc.
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Neurocrine Clinical Site, Saint Charles, Missouri
- Locations
- 39 in total
- Run by
- Neurocrine Biosciences
-
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Neurocrine Clinical Site, Saint Charles, Missouri
- Locations
- 106 in total
- Run by
- Neurocrine Biosciences
-
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, placebo-controlled, …
- Stage
- Phase 2
- Ages
- 18 to 65
- Site
- Autobahn Site #127, Saint Charles, Missouri
- Locations
- 50 in total
- Run by
- Autobahn Therapeutics, Inc.
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.
- Stage
- Phase 4
- Ages
- 18 to 65
- Site
- Clinical Research Site, Saint Charles, Missouri
- Locations
- 40 in total
- Run by
- Axsome Therapeutics, Inc.
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.